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Background. Population-based human immunodeficiency virus type 1 (HIV-1) RNA levels (viral load [VL]) are
proposed metrics for antiretroviral therapy (ART) program effectiveness. We estimated population-based HIV RNA
levels using a fingerprick-based approach in a rural Ugandan community implementing rapid ART scale-up.
Methods. A fingerprick-based HIV RNA measurement technique was validated against standard phlebotomy.
This technique was deployed during a 5-day community-wide health campaign in a 6300-person community. As-
sessments included rapid HIV antibody testing, VL, and CD4+ T-cell count via fingerprick. We estimated popula-
tion HIV RNA levels and the prevalence of undetectable RNA, assessed predictors of VL via linear regression, and
mapped RNA levels within community geographic units.
Results. During the community-wide health campaign, 179 of 2282 adults (7.8%) and 10 of 1826 children
(0.5%) tested seropositive for HIV. Fingerprick VL was determined in 174 of 189 HIV-positive persons (92%). The
mean log(VL) was 3.67 log (95% confidence interval [CI], 3.50–3.83 log copies/mL), median VL was 2720 copies/
mL (interquartile range, <486–38 120 copies/mL), and arithmetic mean VL was 64 064 copies/mL. Overall, 64 of
174 of individuals had undetectable RNA (37% [95% CI, 30%–44%]), 24% had VL 486–10 000; 25% had VL
10 001–100 000; and 15% had VL>100 000 copies/mL. Among participants taking ART, 83% had undetectable VL.
Conclusions. We developed and implemented a fingerprick VL testing method and provide the first report of
population HIV RNA levels in Africa. In a rural Ugandan community experiencing ART scale-up, we found
evidence of population-level ART effectiveness, but found a substantial population to be viremic, in need of ART,
and at risk for transmission.
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Efforts to stem the tide of the human immunodefi-
ciency virus (HIV) epidemic are increasing, with
acceleration of antiretroviral therapy (ART) scale-up
[1] and implementation of combination prevention
strategies [2, 3]. Epidemiologic measurements at a
population or community level—both of the burden
of HIV and of the effectiveness of HIV treatment
strategies—are critical to guiding and monitoring na-
tional and local treatment and prevention strategies.
Population-level HIV type 1 (HIV-1) RNA levels
(viral load [VL]) have been described among individuals
in a geographic area or within specific demographic
groups [4–7]. Population HIV RNA measurements have
the potential to provide insight into the effectiveness of
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ART programs because increased ART penetration and treat-
ment success are associated with lower average VLs and with a
higher proportion of patients with an undetectable VL [4–6].
Because higher VL is correlated with greater infectivity [8, 9],
and since ART-mediated virologic suppression has been
shown to reduce the spread of HIV [10], population RNA
levels may also provide insight into the risk of forward trans-
mission of HIV, acknowledging its known limitations.
To date, reports assessing population HIV RNA levels have
been conducted only in urban settings in the developed world
such as Vancouver, San Francisco, and Washington, D.C. [4–6].
Population-level VLs have not yet been measured in sub-
Saharan Africa, where >23 million persons live with HIV [1].
Several key barriers have precluded population HIV RNA
estimation in resource-limited settings. The high cost of mea-
suring HIV RNA levels is a major impediment to availability.
Apart from South Africa and Botswana [11, 12], VL testing is
thus not used in routine clinical care. Therefore, centralized
data collection systems (eg, clinic databases) that could be used
to estimate population RNA levels lack necessary data on VLs.
Compounding the problem are estimates that up to one-half of
HIV-infected individuals are unaware of their serostatus [1],
and many diagnosed individuals have not successfully linked
to HIV care and ART. Additionally, in rural settings, laborato-
ry facilities are often far from clinics, making blood collection
and cold-chain specimen transport highly challenging.
We sought to address the above challenges and estimate pop-
ulation-level HIV RNA levels in a rural community in south-
western Uganda by measuring VL using a fingerprick blood
collection method during a 5-day community-wide health
campaign offering diagnostic, prevention, and treatment servic-
es for communicable and noncommunicable diseases [13].
This approach may hold potential for assessing the rapid
ongoing ART scale-up in resource-limited settings that do not
offer VL testing during HIV care.
METHODS
Development of Fingerprick-Based Method for HIV-1 Plasma
RNA Measurement
Paired plasma samples were collected from women initiating
ART in Tororo, Uganda, using standard lancet fingerprick
and venipuncture methods. Healthcare workers received in-
person training in these procedures by a laboratory technician,
viewed videos illustrating the procedures, and reviewed written
operating procedures. For standard phlebotomy, 2 mL of
EDTA blood was collected via venipuncture, and plasma was
isolated after centrifugation and stored at −20°C. In parallel,
fingerprick was used to obtain 200 µL of blood via capillary-
Eppendorf hybrid tubes (Safe-T-Fill, Ram Scientific) and
plasma was isolated by centrifugation at 8000g for 10 minutes at
room temperature. Seventy microliters of plasma was removed,
added to 70 µL of phosphate-buffered saline and 560 µL RNA
lysis buffer (AVL buffer, Qiagen), vortexed, then stored at −20°C.
Prior to testing the fingerprick plasma for VL (Abbott RealTime
HIV-1, 0.6-mL protocol), an additional 150 µL of lysis buffer
was added for a final volume of 850 µL. RNA was extracted
using the automated m2000 system (Abbott) following the
manufacturer’s instructions. RNA values and the lower limit of
detection (LLOD; 40 copies/mL) were multiplied by a factor of
12.14 to account for dilution of the fingerprick samples.
Samples with undetectable VL were considered to have 486
copies/mL (40 copies/mL × 12.14, the assay limit of detection).
We assessed the pairwise agreement of fingerprick vs phle-
botomy-derived VL values by Pearson correlation coefficient,
as well as by Bland-Altman analysis.
Community Health Screening and Treatment Campaign
We conducted a 5-day community-wide health campaign
16–21 May 2011 in Kakyerere Parish (Mbarara District, south-
western Uganda), described in detail elsewhere [13]. This
health campaign was approved by the University of California,
San Francisco Committee on Human Research, the Makerere
University School of Medicine Research Ethics Council, and
the Uganda National Council for Science and Technology.
All participants underwent a health questionnaire that asked
about prior knowledge of HIV diagnosis and ART use, had
pretest counseling, and then underwent HIV testing via a fin-
gerprick-derived blood sample (Determine HIV 1/2 antibody
test, Inverness). Persons testing positive who did not report a
history of HIV had immediate confirmatory testing with the
HIV 1/2 STAT-PAK test (Chembio Diagnostic Systems). If a
STAT-PAK result was equivocal or negative, a UniGold Re-
combiGen HIV test (Trinity Biotech) was performed, and a
final HIV diagnosis was determined using all 3 test results ac-
cording to Uganda’s national HIV screening algorithm [14].
HIV-1 Plasma RNA and CD4+ T-Cell Count Measurements
Patients who self-reported a diagnosis of HIV and had a posi-
tive antibody test did not undergo confirmatory testing. In all
participants diagnosed with HIV, a second fingerprick-derived
200-µL blood sample was obtained as described above. Every
2 hours during each campaign day, blood samples were trans-
ported to a central laboratory located in Mbarara (approxi-
mately 25 km from the 3 study sites located in Kakyerere
Parish) and processed for reverse transcription polymerase
chain reaction (RT-PCR) as described above. Samples did not
exceed 4 hours at ambient temperature.
Fingerprick-derived blood was also used to perform a
point-of-care CD4+ T-cell count measurement (PIMA, Alere)
which yields a CD4+ result in 20 minutes and produces
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results concordant with phlebotomy-derived CD4+ counts
[15], particularly at CD4+ counts <500 cells/μL [16].
Antiretroviral Medication Measurement From Dried Blood Spots
During the campaign, Whatman #3 filter paper (GE Health-
care Life Sciences) was used to collect 4 fingerprick samples of
approximately 50 µL of blood (spotted onto filter paper as
dried blood spots (DBSs) and stored in plastic bags with desic-
cant at ambient temperature). In individuals with undetectable
VL or low-level detectable VL (<486 copies/mL), presence of
nevirapine (NVP) and efavirenz (EFV) was tested through
qualitative measurements from DBSs. DBSs were cut from
filter paper and analytes extracted with 80% acetonitrile con-
taining 1% formic acid and an internal standard. After centri-
fugation the solution was analyzed simultaneously on 2
systems. NVP levels were measured qualitatively by liquid
chromatography–tandem mass spectrometry (LLOD, 150 ng/mL).
EFV levels were measured qualitatively by reverse-phase high-
performance liquid chromatography (LLOD, 175 ng/mL).
Classification of ART Use
We classified participants’ ART status by self-report, presence
or absence of ART (EFV or NVP) on DBS testing, and targeted
chart reviews. Individuals who self-reported not being on ART
were reclassified as being on ART if they either (1) had an un-
detectable plasma RNA level and either NVP or EFV was de-
tected, or (2) if chart review documented receipt of ART.
Estimation of Population RNA Metrics
We computed the median VL with interquartile range (IQR),
the mean log(VL), and the arithmetic mean VL among all
HIV-positive participants. We also calculated the median VL/
IQR among persons with detectable viremia. Using an assay
LLOD of 486 copies/mL, we also computed the proportion of
patients with undetectable VL overall, and within demograph-
ic and clinical subgroups.
Geographic Mapping of RNA Levels
Maps from the Ugandan Bureau of Statistics were used to plot
the boundaries of the 7 villages comprising Kakyerere Parish
(Mbarara district, Uganda). Mapping functions were carried
out in ArcGIS. Mean VL within each village was computed
and mapped according to strata of VL. Numbers of HIV-posi-
tive individuals within each village were depicted graphically.
The distance between the approximate centroid of each village
to the district HIV treatment center was calculated.
Statistical Analyses
Individual level associations between log10-transformed VL and
demographic/clinical predictors among HIV-positive persons
were assessed with multivariable linear regression. Using logistic
regression, associations were also assessed between the distance
from each village center to the district health center and
whether individual participants’ VLs were undetectable. All
analyses were performed in Stata 12/SE (StataCorp).
RESULTS
Fingerprick Blood Collection Method
Figure 1A shows a scatterplot of log-transformed VLs from
standard venipuncture/phlebotomy vs fingerprick-derived
specimens. Correlation was strong (Pearson r coefficient =
Figure 1. Standard correlational and Bland-Altman plots assessing relationship of human immunodeficiency virus (HIV)–1 plasma RNA values from
phlebotomy-derived samples with fingerprick-derived samples among 15 HIV-positive persons. A, Standard correlation of log-transformed fingerprick–
derived plasma HIV-1 RNA (ie, viral load) levels (y-axis) vs phlebotomy-derived plasma HIV-1 RNA levels (x-axis). The y-axis is truncated at 6 logs,
though the assay limit of detection is 7 logs. B, Bland-Altman plot. The y-axis displays the difference between the 2 measurements (phlebotomy vs
fingerprick) and the x-axis displays the mean of the 2 measurements. Dashed lines indicate 95% limits of agreement for all pairwise comparisons.
Abbreviation: VL, viral load.
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0.986, P < .0001). Figure 1B is a Bland-Altman mean-diffe-
rence plot depicting the pairwise difference in log(VL)
between the phlebotomy and fingerprick methods on the
y-axis vs the mean of the 2 values on the x-axis. VLs from
fingerprick and standard phlebotomy showed good pairwise
agreement in the detectable range (486–10 000 000 copies/mL)
normalized for original sample dilution (median difference in
log10 copies/mL was 0.039 [5th, 95th percentile, −0.24, 0.32]).
As shown in Figure 1B, VL values were in agreement across a
wide dynamic range ranging from 100 copies/mL to 1 000 000
copies/mL.
Community Health Campaign Study Population
A total of 4343 individuals out of the Kakyerere Parish’s esti-
mated population of 6300 persons (Ugandan Bureau of Statis-
tics data) participated in the community health campaign (69%
coverage of community). In total, 2282 of 2323 (95%) adults
and 1826 of 2020 children (aged 18 months to 17 years, 90%)
were tested for HIV. Overall, 179 of 2282 adults (7.8%), and 10
of 1826 (0.5%) children were HIV seropositive. Of the 189 indi-
viduals who tested positive for HIV, 47% were newly diagnosed
while 53% had been previously diagnosed. Fingerprick VL was
determined in 174 of 189 HIV-positive persons (92%). Demo-
graphics of this population are summarized in Table 1. In brief,
HIV-positive participants were young, with a median age of 30
years (IQR, 24–38), and were predominantly female (73%) and
married (55%), though many were widowed, divorced, or sepa-
rated (31%). Commercial farmers comprised 60% of our popu-
lation. Median CD4+ T-cell count of adults was 415 cells/μL
(IQR, 281–568 cells/μL), and 60% of participants were above
the current Ugandan threshold for ART initiation of 350 cells/
μL. Of 165 adults, 66 were classified as being on ART.
Population-Level HIV RNA Metrics
The median VL was 2720 copies/mL (IQR, <486–38 120
copies/mL), and the mean log(VL) was 3.67 log copies/mL
(95% CI, 3.50–3.83 log). The arithmetic mean VL was 64 064
copies/mL, and the median VL among patients with detectable
viremia was 20 031 copies/mL. Overall, 24% of participants
had VL 486–10 000 copies/mL, 25% had VL 10 001–100 000
copies/mL, and 15% had VL >100 000 copies/mL. 37% of par-
ticipants had undetectable VL (95% CI, 30%–44%). Among
participants on ART, the overall virologic suppression rate was
83%. Table 2 summarizes 4 population-aggregated VL metrics
within subgroups of the population: proportion of participants
with an undetectable VL, median VL, mean log(VL), and the
median VL among subjects with detectable viremia.
Predictors of Virologic Suppression
In individual-level multivariable regression models, receipt of
ART was strongly associated with lower mean VL (−1.45 log,
P < .0001; 990 copies/mL vs 91 651 copies/mL, respectively,
Table 3). Married status was also associated with lower mean
VL (−0.27 log, P = .017). However, although differences in VL
by age, sex, and occupation were evident (Table 2), none of
these was statistically significant in adjusted analyses.
Geographic Mapping of HIV RNA Levels
Figure 2 depicts a map of Kakyerere Parish, with the mean VL
within each of 7 villages categorized by stratum. The number
of participants from each village is depicted graphically, along
with each person’s VL. We assessed whether the distance from
the approximate geographic center of each village to the
Table 1. Baseline Characteristics of Participants Diagnosed

















Peasant farmer 105 (60)
Commercial farmer 2 (1)
Shopkeeper/market vendor 13 (7)
Transport/driver (truck/taxi) 5 (3)
Teacher 4 (2)
Other 36 (21)
Not provided 9 (5)
HIV not previously diagnoseda 72 (44)
Plasma HIV-1 RNA level
Undetectable (≤486 copies/mL) 64 (36.8)
486–10 000 copies/mL 41 (23.6)
10 001–100 000 copies/mL 43 (24.7)
>100 000 copies/mL 26 (14.9)
CD4+ T-cell count,a median (IQR) 415 (281–568)
<200 cells/μL 30 (17)
201–350 cells/μL 42 (24)
>350 cells/μL 102 (59)
Data are presented as No. (%) unless otherwise specified.
Abbreviations: CHC, community health campaign; HIV-1, human
immunodeficiency virus type 1; IQR, interquartile range.
a Based on 165 adults.
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district health center was associated with individuals’ probabil-
ity of having an undetectable VL, but did not find any
association.
DISCUSSION
We report here the estimation of population-based HIV RNA
levels in a rural southwestern Ugandan community of 6300
persons using a fingerprick-based blood collection method for
VL determination. To our knowledge, our report is the first to
estimate population HIV RNA levels in a resource-limited
setting where HIV RNA testing is not part of routine clinical
care. This approach to aggregated population HIV RNA metrics
can help assess the overall impact of ART at a community level.
As expected, the geometric and arithmetic mean VL values
we found were higher than estimates for San Francisco, Van-
couver, and Washington, D.C., and the median value was de-
tectable in our study whereas the median VL was below
detection in these prior studies, indicating that >50% of the
population had virologic suppression. Guidelines in these
well-resourced settings recommend ART initiation at higher
CD4+ T-cell count thresholds, and ART has been available far
longer than in resource-limited settings. In Mbarara, for
example, ART became widely available in 2003–2004; the
CD4+ T-cell count ART threshold had been 200 cells/μL from
that time [17] until it was raised to 250 cells/μL in 2009 [18],
and to 350 cells/μL in 2011 in parallel with shifts in WHO















Overall 174 37 2720 3.67 64 064 20 031
Age <15 9 22 114 869 4.51 223 158 148 788
15–30 69 19 15 515 4.06 85 541 32 050
31–45 23 48 <486 3.32 39 799 10 076
>45 73 61 <486 3.22 14 397 20 237
Sex Female 127 39 2586 3.65 52 947 18 459
Male 47 32 3472 3.72 94 104 46 551
Marital statusa Single 15 13 19 825 4.19 103 115 25 506
Married 95 38 923 3.52 52 742 11 982
Otherb 55 44 2185 3.64 46 938 23 989
No. of children 0 39 36 4528 3.65 57 816 16 061
1–2 78 40 1087 3.56 44 843 19 825
≥3 57 33 4650 3.82 94 642 29 482
Occupation Farmer 107 45 607 3.49 52 702 13 548
Otherc 67 24 16 601 3.95 82 210 33 045
HIVART statusa No ART 99 10 19 048 4.23 100 319 25 506
Receiving ART 66 83 <486 2.71 990 243
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; VL, viral load.
a Assessed in 165 adults.
b Other marital status defined as participants who were single, widowed, divorced, or unspecified.
c Other occupations include those detailed in Table 1.
Table 3. Predictors of HIV-1 Plasma RNA Levels in Patients
Attending a Community-Wide Health Assessment
Variable Univariate Multivariate
Age (+10 y) −0.27 log, P< .001 −0.05 log, P= .29
Female −0.07 log, P= .7 …
Marital status: married −0.32 log, P= .047 −0.27 log, P= .017
No. of children
1–2a −0.09 log, P= .67 …
≥3a −0.17 log, P= .45 …
Occupation: farmerb −0.46 log, P= .005 −0.23 log, P= .06
Receiving ART −1.52 log, P< .001 −1.45 log, P< .001
Patients with undetectable plasma RNA levels were assigned a value of 486
copies/mL, the limit of detection of the assay.
Abbreviations: ART, antiretroviral therapy; HIV-1, human immunodeficiency
virus type 1.
a Comparison reference is to patients with no children.
b Comparison is of patients self-identifying as peasant or commercial farmer
(n = 105) vs other occupations (n = 69).
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guidelines [19]. By contrast, in the United States and Canada,
the recommended ART threshold was 350 cells/μL throughout
most of this period, increasing to 500 cells/μL in late 2009 in
the United States [20, 21]. Furthermore, fewer antiretroviral
medications have been available in Uganda, and the lack of
VL testing has made the detection and management of viro-
logic failure due to drug resistance more challenging. All of
these factors could account for the higher population HIV
RNA levels we observed.
Nevertheless, in our study, 37% of HIV-positive individuals
had an undetectable VL. Viewed against the backdrop of a
recent report from the US Centers for Disease Control and
Prevention estimating that in the United States, only 28% of
all HIV-positive individuals have an undetectable VL [22],
these data from rural Uganda could be viewed as encouraging,
and demonstrate a measure of success of HIV treatment pro-
grams in the region.
Our approach to estimating population HIV RNA levels dif-
fered from those previously reported. In prior estimates, an
aggregate database-driven approach was used to analyze VL
levels captured from large numbers of patients, primarily from
HIV care sites [4–6]. This approach was possible because VL
is routinely measured in clinical practice in these areas and
deposited into a central surveillance database that can be ex-
ploited for VL calculations. Missing data is always a limitation
for any approach, and in San Francisco, investigators used
multiple imputation to generate representative VL values for
persons with missing data [5]. We took a more direct popula-
tion-based approach to VL metrics by offering HIV testing to
all community members (and VL measurement in HIV-
positive persons) during a large-scale health campaign. By per-
forming HIV and VL testing at the same visit, we were able to
capture individuals who might be missing from a clinic-based
analysis because they failed to link to HIV care following
diagnosis.
Our report illustrates that fingerprick collection can be de-
ployed in a rapid, high-throughput fashion in a community
campaign run by locally trained staff and yield useful mea-
surements including reliable HIV RNA levels with an accept-
able LLOD, CD4+ T-cell counts using the PIMA system, and
antiretroviral medication levels from DBSs. However, the
actual assays to measure HIV RNA and antiretroviral drug
levels required transport of fingerprick specimens to a central
laboratory. Second, our technique relied on standard RT-PCR
methods and thus does not harness emerging lower-cost
point-of-care technologies for VL measurement.
Our findings may have implications for the study of HIV
transmission dynamics, as assessing population HIV RNA
levels can help identify groups with higher VLs who are at
increased risk for transmission. Measuring population RNA
levels over time may also be a rapid way to measure the
impact of interventions targeting at-risk groups, using
Figure 2. Geographic mapping of mean human immunodeficiency virus (HIV) RNA levels among 165 individuals with undetectable, midrange, and
high levels of HIV-1 plasma RNA within villages of a rural parish of southwestern Uganda. Mean viral load (VL) for each of 7 villages (names given)
within the parish are displayed in 4 categories. Individual adults (circles, n = 156) and children aged <15 y (squares, n = 9) are depicted in each region
according to VL as follows: undetectable (486 copies/mL) VL (open circles/squares), detectable VL <100 000 copies/mL (black circles/squares), detect-
able VL ≥100 000 copies/mL (red circles/squares). The location of the parish’s level IV government health center is marked at the eastern boundary of
the region (white letter “H” in blue square). Abbreviation: VL, viral load.
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reductions in VL metrics as key outcome variables. Addition-
ally, our geographic mapping of individuals’ VLs, if combined
with behavioral surveys, might illuminate “hot spots” of trans-
mission within communities, providing additional targets for
intervention. Our group is actively engaged in making longitu-
dinal measurements of population RNA levels in southwestern
Uganda within the study community in order to assess how
these are changing over time.
Our findings represent a novel approach to monitoring
ART program performance and ART effectiveness. If effective-
ness represents the result of a successful “cascade of care” [22],
from HIV diagnosis to linkage to care, followed by ART initi-
ation, retention in care, and virologic suppression, population
HIV RNA levels are a downstream metric that integrates these
drivers and other factors that are more difficult to measure.
These include the proportion of a population on ART, the du-
rability of ART regimens, adherence levels, and drug resistance
causing ART failure. In this manner, population RNA levels
may be a valuable summary metric that can inform policy
makers on the impact of interventions in a region or
population.
Our study was unable to detect persons with acute HIV in-
fection, a limitation that should be addressable in the future
by point-of-care tests that can diagnose some individuals who
are viremic but who have not yet seroconverted. Another limi-
tation was that only 52% of community men were tested, com-
pared with 95% of women [13]. This may have been due to
competing demands of work, testing stigma [23], the phenom-
enon of men “testing by proxy” (ie, inferring HIV status via
their partners’ results) [24], or suboptimal mobilization of
men [25]. Failure to capture a larger proportion of men may
lead to biases—either upward or downward—in the estimated
RNA metrics in this report. Downward bias may have oc-
curred, for example, if missing individuals were less likely to
be engaged in care, on ART, and virologically suppressed,
whereas upward bias may have occurred if missing individuals
were more likely to be in care and on ART and did not attend
the campaign because they already knew their HIV status.
Subsequent campaigns have successfully addressed several of
these barriers in recruiting men.
In summary, by offering HIV testing at a community health
campaign in a defined geographic population and measuring
VL on all HIV-infected persons using a fingerprick blood col-
lection technique, we were able to estimate population HIV
RNA levels in a resource-limited setting that does not have
routine VL testing in its HIV clinics. This strategy may allow
for measurements of HIV epidemiology and HIV transmission
dynamics at the population level in areas of the world with the
highest burden of HIV, and may be a valuable tool in evaluat-
ing the reach, scope, and effectiveness of ART delivery pro-
grams at the community level.
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